Evotec holds 2026 guidance as Q3 adjusted EBITDA loss narrows to €1.6 million
Evotec via Ad-Hoc-News · · AI-summarised by FinFlash
Evotec reported third-quarter revenue of €164.9 million, little changed from €163.9 million, while adjusted group EBITDA improved to a €1.6 million loss from a €15.0 million loss. Nine-month revenue fell 13.1% to €465.0 million and adjusted EBITDA loss widened to €44.3 million. The German drug-discovery group reaffirmed 2026 guidance of €570-610 million revenue and an adjusted EBITDA loss of €70-105 million, with liquidity at €400.9 million and a strategic review ongoing.
So What?
Narrowing losses help the turnaround case, but the wide negative EBITDA guide implies a weak fourth-quarter bar. Watch the strategic review outcome.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.